Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 5/20 | 0.35 |
| ▸ | PDE2A | O00408 | 1/20 | 0.34 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | CARM1 | Q86X55 | 3/20 | 0.32 |
| ▸ | PRMT1 | Q99873 | 3/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.31 |
| ▸ | METAP2 | P50579 | 1/20 | 0.30 |
| ▸ | METAP1 | P53582 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20030770 | 0.86 | CHRM1 (0.35) | CHRM1PDE2APDE11AGRM2MAPK1 | |
| SCHEMBL19260906 | 0.81 | CHRM1 (0.42) | CHRM1PDE2APDE11APDE10A | |
| SCHEMBL20030878 | 0.79 | CHRM1 (0.39) | CHRM1 | |
| SCHEMBL23672778 | 0.73 | CHRM1 (0.57) | CHRM1PDE2APDE11A | |
| SCHEMBL23695832 | 0.72 | CHRM1 (0.54) | CHRM1PDE2APDE11APDE10A | |
| SCHEMBL23672646 | 0.72 | CHRM1 (0.60) | CHRM1PDE2APDE11A | |
| SCHEMBL23672737 | 0.72 | CHRM1 (0.52) | CHRM1PDE2APDE11AMAPK1 | |
| SCHEMBL23672867 | 0.72 | CHRM1 (0.61) | CHRM1PDE2APDE11A | |
| SCHEMBL19268069 | 0.71 | CHRM1 (0.47) | CHRM1PDE2APDE11APDE10A | |
| SCHEMBL23672679 | 0.70 | CHRM1 (0.50) | CHRM1PDE2APDE11AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3416639-B1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | UNIV VANDERBILT (US) | 2022-06-08 | — | — | EP | disclosed |
| EP-3416639-B1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | UNIV VANDERBILT (US) | 2022-06-08 | — | — | EP | disclosed |
| US-11111251-B2 | Positive allosteric modulators of the muscarinic acetylcholine receptor M1 | VANDERBILT UNIVERSITY (US) | 2021-09-07 | — | — | US | disclosed |
| US-11111251-B2 | Positive allosteric modulators of the muscarinic acetylcholine receptor M1 | VANDERBILT UNIVERSITY (US) | 2021-09-07 | — | — | US | disclosed |
| US-20210230180-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | VANDERBILT UNIVERSITY | 2021-07-29 | — | — | US | disclosed |
| US-20210230180-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | VANDERBILT UNIVERSITY | 2021-07-29 | — | — | US | disclosed |
| WO-2017143041-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | VANDERBILT UNIVERSITY (US) | 2017-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210230180-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | CHRM1, CHRM2, CHRM4 | CHRM1 1/4885PDE2A 513/4885PDE11A 920/4885 |
| US-11111251-B2 | Positive allosteric modulators of the muscarinic acetylcholine receptor M1 | CHRM1, CHRM2, CHRM4 | CHRM1 1/4885PDE2A 513/4885PDE11A 920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.